Ensysce Q3 net loss narrows to $2.7M; cash $1.5M; PF614 study results expected by year-end

Ensysce Biosciences, Inc.

2023-Q3 EPS reported -$3.32 revenue$1,715,488

Net loss attributable to common stockholders was $2.7M ($0.87/share) vs $9.9M ($61.58) in Q3 2022.
Cash and cash equivalents $1.5M as of Sep 30, 2023, down from $3.8M at June 30; post-quarter raised $1.7M in convertible notes.
R&D expenses fell to $1.9M from $4.8M; G&A expenses fell to $1.2M from $1.7M.
PF614-201 time-of-onset study results expected in December 2023; FDA End of Phase 2 meeting set for Jan 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.